Press release content from PR Newswire. The AP news staff was not involved in its creation.
Centene Corporation Announces Results of Cash Tender Offer for Any and All of its 4.75% Senior Notes due 2025
February 18, 2021 GMT
ST. LOUIS, Feb. 18, 2021 /PRNewswire/ Centene Corporation (NYSE: CNC) (“Centene” or the “Company”) announced the results of its previously announced tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding $2,200,000,000 aggregate principal amount of 4.75% Senior Notes due 2025 (the “2025 Notes”) from each registered holder of the 2025 Notes (the “Holders”), which expired as of 5:00 p.m., New York City time, on February 17, 2021 (the “Expiration Time”). The Tender Offer was made pursuant to an Offer to Purchase, dated February 10, 2021 (the “Offer to Purchase”), and the related letter of transmittal and notice of guaranteed delivery for the Tender Offer (together with the Offer to Purchase, the “Offer
Press release content from Accesswire. The AP news staff was not involved in its creation.
Noram Completes CVZ-65: High of 1820 ppm Intersection of 270ft (82.3m) Averaging 1124ppm of Lithium
February 18, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / February 18, 2021 / Noram Ventures Inc. ( Noram or the Company ) (TSXV:NRM)(Frankfurt:N7R)(OTCQB:NRVTF) is pleased to announce the successful completion of CVZ-65. The Company completed core hole CVZ-65 at a depth .
VANCOUVER, BC / ACCESSWIRE / February 18, 2021 / Noram Ventures Inc. ( Noram or the Company ) (TSXV:NRM)(Frankfurt:N7R)(OTCQB:NRVTF) is pleased to announce the successful completion of CVZ-65. The Company completed core hole CVZ-65 at a depth .
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant .
Sumitovant BiopharmaFebruary 18, 2021 GMT
New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine published Myovant Sciences’ Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. As previously reported, both studies achieved the primary endpoint of response rates in menstrual blood loss in addition to six of the seven key secondary endpoints, while maintaining bone mineral density comparable to placebo as part of a well-tolerated safety profile over 24 weeks.
HONG KONG — Hong Kong is reducing social distancing rules following a sharp drop in new coronavirus cases, including restarting indoor dining and reopening gyms.